Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Overview

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

SparkCures ID 1107
Trial Phase Phase 2
Enrollment 27 Patients
Treatments
Trial Sponsors
  • Herbert Irving Comprehensive Cancer Center
Trial Collaborators
  • Genzyme, a Sanofi Company
NCT Identifier

NCT04614558

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Renal biopsy proven diagnosis of an MGRS disorder including the following:

    1. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)
    2. C3 glomerulopathy associated with monoclonal gammopathy
    3. Non-Amyloid Fibrillary Glomerulonephritis
    4. Light chain Proximal Tubulopathy
    5. Immunotactoid Glomerulopathy

    A concurrent diagnosis of Monoclonal gammopathy (with +ve Serum and/or Urine protein electrophoresis or Bone marrow biopsy) is required in patients with C3 glomerulopathy but not for other disorders. Patients with concurrent MGUS, non-high risk smoldering myeloma are eligible for enrollment.

  2. Measurable Proteinuria ≥1gram over 24 hours.
  3. Prior Therapy: Newly diagnosed as well as patients with previous therapy but persistent renal dysfunction and persistent proteinuria ≥1gram over 24 hours are eligible for enrollment. Patients who received a prior cluster of differentiation 38 (CD38) antibody therapy are not eligible for study. In patients who have received prior therapy a wash out period of 12 weeks for chemotherapy based therapies and 24 weeks for Rituximab based therapies is required between completion of prior therapy and cycle 1 Day1 of study therapy.
  4. Age ≥18 years.
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  6. Life expectancy of greater than 6 months
  7. Participants must have normal organ and marrow function as defined below:

Leukocytes ≥3,000/microliters (mcL)

  1. absolute neutrophil count ≥1,500/mcL
  2. platelets ≥100,000/mcL
  3. total bilirubin within normal institutional limits
  4. Aspartate aminotransferase (AST) (SGOT)/alanine transaminase (ALT)(SGPT) ≤2.5 × institutional upper limit of normal
  5. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2.

Exclusion Criteria:

  1. Participants who have had chemotherapy based therapy within 12 weeks or Rituximab based therapy within prior 24 weeks prior to starting the cycle 1 Day 1 of trial therapy
  2. Participants who are receiving any other investigational agents concurrently.
  3. History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
  4. Diagnosis of Multiple Myeloma or High risk smoldering Multiple Myeloma or a B cell lymphoma meeting criteria for therapy.
  5. Renal Biopsy showing the coexistence of other significant diagnosis e.g. diabetic nephropathy.
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Pregnant and Lactating women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Isatuximab.
  8. HIV-positive Participants are ineligible because of increased risk of lethal infections when treated with immunosuppressive therapy.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

New York
Pennsylvania

Resources

There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message